Urology Doctors in Coeur D Alene, ID Accepting Medicare

5 Urology doctors found. Showing 1 - 5

Roxanne Haslam, MD Urology Medicare: Medicare Enrolled Practice Location: 980 W Ironwood Dr Ste 104, Coeur D Alene, ID 83814 Phone: 208-667-0621    Fax: 208-664-1709

Matthew David Mclaughlin, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 980 W Ironwood Dr, Ste 104, Coeur D Alene, ID 83814 Phone: 208-667-0621    Fax: 208-664-1709

Ian William Udell, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 980 W Ironwood Dr Ste 104, Coeur D Alene, ID 83814 Phone: 208-667-0621

Dr. Chad Allan Peterson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 980 W Ironwood Dr, Ste. 104, Coeur D Alene, ID 83814 Phone: 208-667-0621    Fax: 208-664-1709

David Flores, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 980 W Ironwood Dr Ste 104, Coeur D Alene, ID 83814 Phone: 208-667-0621    Fax: 208-664-1709

News Archive

Innovation of the Year: Littmann Electronic Stethoscope Model 3200 with Zargis Cardioscan software

3M Health Care and Zargis Medical, a majority-owned subsidiary of Speedus Corp. (Nasdaq:SPDE), announced today that the 3M™ Littmann® Electronic Stethoscope Model 3200 with Zargis Cardioscan™ software was named Popular Science's "Innovation of the Year." This prestigious honor, part of the publication's annual "Best of What's New Awards," highlights outstanding innovation, vision and execution in technologic, scientific and medical advances for the year.

Physical therapy in ICU can reduce hospital stays

The results of the first study to show the effectiveness of early physical therapy in a medical intensive care unit (ICU) were presented by a researcher from Wake Forest University Baptist Medical Center at the national meeting of the American College of Chest Physicians in Chicago.

FDA requests a budget of $4.5 billion to protect and promote public health

The U.S. Food and Drug Administration is requesting a budget of $4.5 billion to protect and promote the public health as part of the President's fiscal year (FY) 2013 budget – a 17 percent increase over the FDA enacted budget for FY 2012.

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

Read more Medical News

› Verified 4 days ago